TAKE A LOOK AT WHICH REPORT YOUR PORTFOLIO'S BEEN MISSING...

Shareholders Foundation offers real-time reporting of class action exposure on a per transaction basis,
including the documents you will need for claim filing and settlement recovery.
Start Monitoring Your Investments

OvaScience Inc (NASDAQ:OVAS) Investor Investigation Concerning Potential Violations Of Securities Laws Announced

  • If you purchased shares of OvaScience Inc (NASDAQ:OVAS), you have certain options and you should contact the Shareholders Foundation, Inc.

  • To have your information reviewed for options and to receive notifications about this investigation, please send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.

Investigation Overview

Company
OvaScience Inc
Security
NASDAQ: OVAS

Summary

October 06, 2015 (Shareholders Foundation) - An investigation on behalf of investors of OvaScience Inc (NASDAQ:OVAS) shares over potential securities laws violations by OvaScience and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of OvaScience Inc (NASDAQ:OVAS) concerning whether a series of statements by OvaScience Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

OvaScience Inc reported that its annual Net Loss increased from $13.51 million in 2012 to $49.52 million in 2014.

On January 8, 2015, OvaScience Inc conducted a Secondary Offering (the 'Offering'), selling 2.3 million shares of the Company's common stock at $50 per share.

On March 26, 2015, OvaScience Inc announced that presentations by fertility specialists offering the Companys AUGMENTSM fertility treatment reported encouraging pregnancy rates in women who previously failed multiple cycles of in vitro fertilization (IVF). OvaScience Inc said that Clinical reports from two international IVF clinics will be featured at the Society for Reproductive Investigation (SRI) 62nd Annual Scientific Meeting.

On Mar. 28, 2015, OvaScience Inc announced that additional clinical experience of the Companys AUGMENTSM treatment demonstrated improved pregnancy rates in women who had failed three to seven prior in vitro fertilization (IVF) cycles. OvaScience Inc said that these results were reported at the Society for Reproductive Investigation (SRI) 62nd Annual Scientific Meeting being held in San Francisco, CA.

On September 28, 2015, OvaScience Inc provided an update on its corporate goal for AUGMENT treatment. OvaScience Inc announced that it does not expect to meet the 2015 goal of 1,000 AUGMENTSM treatment cycles.

Shares of OvaScience Inc (NASDAQ:OVAS) declined from over $50 per share in early 2015 to as low as $7.90 per share on September 30, 2015.

Start Monitoring Your Investments